Cormorant Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Cormorant Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-500,000	Closed	-$27M	–	59
2017 Q3	$27M	Sell	500,000 -400,000	-44%	-$23.5M	4.77%	6
2017 Q2	$50.6M	Buy	900,000 +300,000	+50%	+$12M	8.38%	1
2017 Q1	$23.5M	Buy	600,000 +63,000	+12%	+$2.01M	3.41%	9
2016 Q4	$12.1M	Sell	537,000 -59,000	-10%	-$1.15M	1.62%	21
2016 Q3	$13.5M	Buy	596,000 +200,000	+51%	+$4.69M	1.49%	24
2016 Q2	$9.35M	Sell	396,000 -304,000	-43%	-$7.51M	1.33%	27
2016 Q1	$14.3M	Buy	700,000 +200,000	+40%	+$6.35M	2.15%	13
2015 Q4	$25.7M	Hold	500,000	–	–	3.08%	8
2015 Q3	$21.3M	Hold	500,000	–	–	3.4%	9
2015 Q2	$22.8M	Sell	500,000 -74,500	-13%	-$3M	3.03%	10
2015 Q1	$21.8M	Sell	574,500 -25,500	-4%	-$876K	3.37%	7
2014 Q4	$17M	Buy	600,000 +400,000	+200%	+$11.1M	2.62%	12
2014 Q3	$5.06M	Hold	200,000	–	–	1.04%	30
2014 Q2	$5.84M	Hold	200,000	–	–	1.55%	23
2014 Q1	$5.18M	Buy	200,000 +125,000	+167%	+$3.34M	1.19%	30
2013 Q4	$1.93M	Buy	+75,000	New	+$1.82M	0.56%	29

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Cormorant Asset Management's PTLA Position: Q4 2017 in Review

Cormorant Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 500,000 shares — an estimated $27M sold.

Cormorant Asset Management first reported a position in PTLA in Q4 2013 and held it in 16 quarters. The position peaked at $50.6M in Q2 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

Cormorant Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Cormorant Asset Management sold 500,000 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $27M.
Cormorant Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 16 quarters.
Cormorant Asset Management's Portola Pharmaceuticals, Inc. position peaked at $50.6M in Q2 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.